Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1968 2
1972 2
1984 2
1985 2
1986 4
1987 1
1988 1
1989 1
1990 1
1994 1
1995 1
1996 1
1997 3
2003 1
2004 2
2005 1
2006 3
2007 2
2008 3
2009 4
2010 5
2011 11
2012 7
2013 9
2014 6
2015 8
2016 3
2017 11
2018 7
2019 11
2020 16
2021 19
2022 19
2023 16
2024 12
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Results by year

Filters applied: . Clear all
Page 1
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.
Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Sawada K, Taniguchi H, Fuse N, Nomura S, Fukui M, Matsuda S, Sakamoto Y, Uchigata H, Kitajima K, Kuramoto N, Asakawa T, Olsen S, Odegaard JI, Sato A, Fujii S, Ohtsu A, Yoshino T. Nakamura Y, et al. Among authors: yuki s. Nat Med. 2021 Nov;27(11):1899-1903. doi: 10.1038/s41591-021-01553-w. Epub 2021 Nov 11. Nat Med. 2021. PMID: 34764486 Free PMC article. Clinical Trial.
Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.
Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, Uebayashi M, Okuda H, Kusumi T, Miyagishima T, Sogabe S, Tateyama M, Hatanaka K, Tsuji Y, Nakamura M, Konno J, Yamamoto F, Onodera M, Iwai K, Sakata Y, Abe R, Oba K, Sakamoto N. Kobayashi Y, et al. Among authors: yuki s. Future Oncol. 2015;11(4):617-27. doi: 10.2217/fon.14.251. Future Oncol. 2015. PMID: 25686117 Clinical Trial.
The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine.
Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, Ozaki H, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Taniguchi H, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Otsuka T, Hara H, Okano N, Nishina T, Sakamoto Y, Miki I, Kobayashi S, Yuda J, Kageyama SI, Nagamine M, Sakashita S, Sakamoto N, Yamashita R, Koga Y, Bando H, Ishii G, Kuwata T, Park WY, Ohtsu A, Yoshino T. Hashimoto T, et al. Among authors: yuki s. Cancer Discov. 2024 Nov 1;14(11):2243-2261. doi: 10.1158/2159-8290.CD-24-0206. Cancer Discov. 2024. PMID: 39023403 Free PMC article.
Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, Fukuoka S, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Wakabayashi M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Suzuki Y, Sato A, Nishikawa H, Ito M, Yoshino T. Bando H, et al. Among authors: yuki s. Clin Cancer Res. 2022 Mar 15;28(6):1136-1146. doi: 10.1158/1078-0432.CCR-21-3213. Clin Cancer Res. 2022. PMID: 35063964 Free PMC article.
Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors.
Nakamura Y, Ozaki H, Ueno M, Komatsu Y, Yuki S, Esaki T, Taniguchi H, Sunakawa Y, Yamaguchi K, Kato K, Denda T, Nishina T, Takahashi N, Satoh T, Yasui H, Satake H, Oki E, Kato T, Ohta T, Matsuhashi N, Goto M, Okano N, Ohtsubo K, Yamazaki K, Yamashita R, Iida N, Yuasa M, Bando H, Yoshino T. Nakamura Y, et al. Among authors: yuki s. Nat Med. 2025 Jan;31(1):165-175. doi: 10.1038/s41591-024-03244-8. Epub 2024 Sep 16. Nat Med. 2025. PMID: 39284955 Free PMC article.
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.
Iida N, Imai M, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Taniguchi H, Nonomura N, Sunakawa Y, Shiozawa M, Yamazaki K, Boku S, Bando H, Shiraishi Y, Kobayashi M, Goto H, Sato A, Fujii S, Yoshino T, Nakamura Y. Iida N, et al. Among authors: yuki s. Clin Cancer Res. 2024 Sep 13;30(18):4167-4178. doi: 10.1158/1078-0432.CCR-24-1023. Clin Cancer Res. 2024. PMID: 39163021 Free PMC article.
Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
Tsukada Y, Bando H, Inamori K, Wakabayashi M, Togashi Y, Koyama S, Kotani D, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Sato A, Nishikawa H, Ito M, Yoshino T. Tsukada Y, et al. Among authors: yuki s. Br J Cancer. 2024 Jul;131(2):283-289. doi: 10.1038/s41416-024-02730-7. Epub 2024 Jun 4. Br J Cancer. 2024. PMID: 38834744 Clinical Trial.
Dynamics of memory engrams.
Takamiya S, Yuki S, Hirokawa J, Manabe H, Sakurai Y. Takamiya S, et al. Among authors: yuki s. Neurosci Res. 2020 Apr;153:22-26. doi: 10.1016/j.neures.2019.03.005. Epub 2019 Mar 30. Neurosci Res. 2020. PMID: 30940458
A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801.
Nakatsumi H, Komatsu Y, Harada K, Kawamoto Y, Yuki S, Sawada K, Ishiguro A, Sogabe S, Ando T, Sasaki Y, Yoshikawa A, Nakamura M, Dazai M, Tateyama M, Muto O, Kotaka M, Sagawa T, Muranaka T, Hatanaka K, Takagi R, Sakata Y. Nakatsumi H, et al. Among authors: yuki s. Int J Cancer. 2024 Dec 15;155(12):2223-2231. doi: 10.1002/ijc.35116. Epub 2024 Aug 14. Int J Cancer. 2024. PMID: 39143041 Clinical Trial.
Edaravone and its clinical development for amyotrophic lateral sclerosis.
Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J. Takei K, et al. Among authors: yuki s. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):5-10. doi: 10.1080/21678421.2017.1353101. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 28872907 Free article. Review.
186 results